This is a joint European project with participants from Germany, Italy and Norway that is related to celiac disease
(CeD). CeD is a common food-induced inflammatory disease of the small intestine that caused by ingestion of gluten
from wheat, barley and rye. The only effective treatment available is a strict lifelong gluten-free (GF) diet. GF
products for CeD patients must not exceed the regulatory threshold of 20 mg/kg of gluten. Compliance of foods is
typically assessed with an enzyme-linked immunosorbent assay (ELISA), but this assay performs less well in food
products with fermented or partially hydrolysed gluten. The objectives of this joint European project will address this
issue.
In the project we will provide a comprehensive and unique toolbox of novel and validated methods to detect gluten
(both intact and partially hydrolysed) in foods for CeD patients. This will be achieved by using discovery proteomics
and quantitative LC-MS/MS methods, improved reference materials for partially hydrolysed gluten, CeD-patient
derived monoclonal antibodies and functional gluten-specific T-cell assays. This Norwegian partner will specifically
work on performing clinical challenges of CeD-patients.